Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Haisco Pharmaceutical enters into a licensing agreement with Sentivera, securing $75.89 million in upfront and equity consideration. This collaboration enhances Haisco's strategy for international innovation in drug development.

Aug 26, 2026•about 4 hours ago
ChinaBiotechnologyHealth CarePharmaceutical

Description

Haisco Pharmaceutical Group announced an exclusive licensing agreement with Sentivera, granting rights to develop a preclinical innovative drug. The total deal is valued at over $1.5 billion, including $75.89 million upfront. This partnership aims to boost Haisco's international strategy and generate long-term investment returns. It underscores strong market confidence in the project, contributing to the internationalization of innovative drugs from China.

Company Information

Company

Haisco Pharmaceutical Group Ltd

Location

China

About

Haisco Pharmaceutical Group Co., Ltd. is a benchmark enterprise in China's innovative drug sector, focusing on innovation-driven growth and global expansion. The company has a diversified R&D pipeline with more than 70 programs across therapeutic areas such as immunology, oncology, and metabolic disorders. Haisco is committed to advancing its R&D efforts, with substantial investments aimed at developing original medicines to address unmet clinical needs globally.

Predictive Intelligence
Strategic

ML-powered predictions for Haisco Pharmaceutical Group Ltd's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Haisco Pharmaceutical Group Ltd signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.